The ImmunityBio COVID-19 vaccine, codenamed hAd5, is a non replicating viral vector [1] COVID-19 vaccine developed by the United States-based pharmaceutical company ImmunityBio. [2] [1]
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Trade names | hAd5 |
The BioVac Institute, a state-backed South African vaccine company, plans to use a deal it won to manufacture coronavirus vaccines. The contract with American based ImmunityBio Inc is currently conducting phase 1 vaccine trials in South Africa [3]
ImmunityBio and BioVac plan to distribute the vaccines throughout South Africa and Africa. [4] [5]
In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine. [6]
On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund monkey trials. [7] The company "hope to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020." [7]
ImmunityBio Inc is currently conducting phase 1 vaccine trials in The United States and South Africa. [3] [8] [9][ needs update]
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|